Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

news.bms.com

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy...

  • Press Release: Lisp-cell meets primary endpoint of EFS over Auto after first relapse in DLBCL. OS data not yet mature. very limited data currently available for review, but hopefully we will see it presented at ASH.